RCK-8 and RIVA, DLBCL cell lines with lower SAMHD1 expression showed, in general, greater sensitivity to Veliparib as compared to SUDHL-4 and SUDHL-6, DLBCL cell lines with higher SAMHD1 expression as determined with a PI/Annexin V assay where live cells were considered (Figure 1B and Supplementary Figure S1A). The gene discussed is ANXA5; the disease is diffuse large B-cell lymphoma.